#United States #San Diego #Robbins LLP #Humacyte #ATEV

Class Action Alert for Humacyte, Inc. Investors

Robbins LLP, a law firm specializing in shareholder rights, is alerting investors about a significant class action lawsuit against Humacyte, Inc. (NASDAQ: HUMA). This action affects all individuals and organizations that acquired Humacyte securities between May 10, 2024, and October 17, 2024. The lawsuit centers on serious allegations that the company misled investors regarding its manufacturing practices, particularly concerning its acellular tissue-engineered vessels.

Background on Humacyte, Inc.

Humacyte Inc. is engaged in the development of innovative bioengineered human tissues, including implantable vessels utilized in medical procedures. Their flagship product, the Acellular Tissue Engineered Vessel (ATEV), purports to offer a lab-grown alternative for damaged blood vessels, presenting an exciting advancement in vascular surgery.

However, the company faced significant scrutiny when it was reported that the FDA required additional time to review its Biologic License Application (BLA) for ATEV. A press release from the company acknowledged ongoing inspections of their manufacturing practices, suggesting that their Durham, North Carolina facility may not have met essential FDA standards.

Allegations Laid Out in the Class Action

The class action has emerged in response to claims that Humacyte failed to disclose crucial information to its investors. Key allegations include:
1. The company's manufacturing facility did not comply with good manufacturing practices, lacking essential quality assurance and microbial testing protocols.
2. The FDA's evaluation of the BLA would be delayed as Humacyte worked to address these deficiencies.
3. There was a substantial risk that the ATEV's approval for vascular trauma would be jeopardized due to these issues.

These allegations were substantiated when, on October 17, 2024, a Form 483 was issued by the FDA, outlining deficiencies observed during an inspection of Humacyte's manufacturing site, revealing alarming violations that prompted further declines in the company's stock price.

Impact on Humacyte's Stock and Investor Losses

As a result of these revelations, Humacyte's stock price plummeted. Following the announcement of the FDA's additional scrutiny, shares dropped by 16.4%, and continued to decline significantly with the release of the Form 483. Such drastic fluctuations have left many investors facing substantial losses.

Opportunities for Affected Investors

Investors who have suffered significant losses in Humacyte shares during this window may be eligible to take part in this class action. Those wishing to step forward as lead plaintiffs in the case must submit their application by January 17, 2025. Being a lead plaintiff allows a shareholder to represent the interests of other investors in the class action.

No financial commitment is required to participate, as Robbins LLP operates on a contingency fee basis, ensuring that shareholders are not liable for fees unless a recovery is achieved. Interested parties are encouraged to reach out for more information, with the assurance that it is possible to remain an absent class member while still being eligible for any future recovery.

About Robbins LLP

Established in 2002, Robbins LLP is a recognized leader in litigating shareholder rights, committed to helping investors recover incurred losses and uphold corporate accountability. The firm has successfully reclaimed over $1 billion for shareholders in various litigation cases to date. To stay updated or claim your eligibility, sign up for Stock Watch for immediate notifications if the class action settlement occurs or if shareholders encounter further wrongdoing from executives within the firm.

In conclusion, if you purchased Humacyte, Inc. shares during the specified time period and believe your investment has been affected by significant management misrepresentation, engaging with Robbins LLP could provide critical support and recovery avenues for your losses.